Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.76 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12476306 | 1.00 | EPHX2 (0.76) | EPHX2APLNRNR1H2ALDH1A1BRD4 | |
| SCHEMBL17691129 | 1.00 | EPHX2 (0.76) | EPHX2APLNRNR1H2ALDH1A1BRD4 | |
| SCHEMBL765006 | 0.97 | — | — | |
| SCHEMBL15369942 | 0.97 | — | — | |
| SCHEMBL1064821 | 0.97 | — | — | |
| SCHEMBL10044382 | 0.94 | EPHX2 (0.68) | EPHX2APLNRNR1H2ALDH1A1BRD4 | |
| SCHEMBL5243600 | 0.94 | EPHX2 (0.68) | EPHX2APLNRNR1H2ALDH1A1BRD4 | |
| SCHEMBL28619137 | 0.94 | EPHX2 (0.68) | EPHX2APLNRNR1H2ALDH1A1BRD4 | |
| SCHEMBL10775671 | 0.84 | EPHX2 (0.58) | EPHX2NR1H2 | |
| SCHEMBL13921587 | 0.84 | EPHX2 (0.58) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120034248-A1 | NOVEL AGONISTS OF TOLL-LIKE RECEPTOR 3 AND METHODS OF THEIR USE | IDERA PHARMACEUTICALS, INC. | 2012-02-09 | — | — | US | disclosed |
| US-20110082186-A1 | COMPOSITIONS FOR INHIBITING GENE EXPRESSION AND USES THEREOF | IDERA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20100098685-A1 | Use of Inhibitors of Toll-Like Receptors in the Prevention and Treatment of Hypercholesterolemia and Hyperlipidemia and Diseases Related Thereto | IDERA PHARMACEUTICALS, INC. (US) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098685-A1 | Use of Inhibitors of Toll-Like Receptors in the Prevention and Treatment of Hypercholesterolemia and Hyperlipidemia and Diseases Related Thereto | TLR1, TLR4, TLR3 | EPHX2 2786/4885APLNR 395/4885NR1H2 27/4885 |
| US-20120034248-A1 | NOVEL AGONISTS OF TOLL-LIKE RECEPTOR 3 AND METHODS OF THEIR USE | TLR3, TLR9, TLR1 | EPHX2 4143/4885APLNR 62/4885NR1H2 356/4885 |
| US-20110082186-A1 | COMPOSITIONS FOR INHIBITING GENE EXPRESSION AND USES THEREOF | RNGTT, NSUN2, RTCB | EPHX2 2243/4885APLNR 2125/4885NR1H2 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.